Clinical Trials

United States – October 27, 2026 -- Families affected by Duchenne muscular dystrophy have early data on SGT-003, an investigational gene therapy from Solid Biosciences: 90 days after dosing, three boys showed average microdystrophin expression of 110%.

Three boys show muscle health improvements at 90 days

The Phase 1/2 INSPIRE DUCHENNE study reported initial data from its first three patients: two 5-year-old boys and one 7-year-old boy. Beyond microdystrophin expression, the company observed reductions in the muscle injury markers CK, AST, ALT, Titin, LDH and eMHC. It describes this as potential stabilization of muscle health.

The company also reports promising signs of muscle function preservation and encouraging early findings in potential cardiac benefit. Heart health is critically important in Duchenne. The company calls its outlook one of cautious optimism.

United States – October 29, 2026 -- Solid Biosciences has dosed 33 children aged 1 to 10 with its investigational gene therapy SGT-003 for Duchenne muscular dystrophy, and a Phase 3 trial has enrolled its first patient.

Safety data show no liver, kidney or heart-inflammation cases

The figures come from INSPIRE DUCHENNE, a Phase 1/2, open-label, multi-center study, with data cut off on January 9, 2026. SGT-003 has been generally well tolerated using prophylactic steroids alone for immune suppression. The company reports no cases of drug-induced liver injury, thrombotic microangiopathy, atypical hemolytic uremic syndrome or myocarditis.

Cardiac monitoring has shown consistent reductions in markers of cardiac injury, with early signals of normalization. The company also reports microdystrophin expression and improvements across multiple biomarkers of muscle health.

Leipzig – October 29, 2026 -- Expectant parents can now have placental tissue frozen for possible future medical use: since summer 2026, Vita 34 has offered private storage of placental tissue alongside its existing umbilical cord blood and cord tissue services.

Vita 34 deep-freezes the complete placental tissue after birth

After delivery, the tissue is processed and frozen at very low temperatures, a method called cryopreservation. The goal is to preserve the cell populations in the tissue and their biological potential over the long term. Whether the stored cells can ever be used, and for which conditions, depends on future scientific progress and on therapies that are approved later.

Vita 34 says it stores the full placental tissue, so that different cell types are retained for possible future applications.

Boston – October 28, 2026 -- People living with Friedreich's ataxia (FA) have a new gene therapy candidate heading toward human testing: Solid Biosciences says the FDA has cleared its Investigational New Drug (IND) application for SGT-212, with a Phase 1b trial planned for the second half of 2025.

SGT-212 attacks FA through two delivery routes

The company describes SGT-212 as the first gene therapy in the industry to use a dual route of administration. It delivers full-length frataxin protein in two ways:

United States – October 28, 2026 -- Solid Biosciences has dosed 40 participants with its Duchenne gene therapy SGT-003 and reported positive interim safety and biomarker data from the ongoing Phase 1/2 INSPIRE DUCHENNE trial. The company presented the update at the 2026 MDA Clinical & Scientific Conference.

The therapy delivers a shortened dystrophin protein

SGT-003 delivers microdystrophin, a shortened version of dystrophin designed to help support and protect muscle cells during movement. The data show robust microdystrophin expression. They also show restoration of beta-sarcoglycan and nNOS, proteins that normally work with dystrophin in the dystrophin-associated protein complex (DAPC), the muscle cell support system.

United States – October 27, 2026 -- Solid Biosciences has expanded its INSPIRE DUCHENNE gene therapy trial to 43 participants and now accepts children aged 4 to under 12, up from the previous range of 4 to under 8.

Three participants dosed with no serious adverse events

INSPIRE DUCHENNE is a first-in-human, multicenter, Phase 1/2 open-label study. It tests the safety, tolerability and efficacy of a single intravenous infusion of SGT-003, a next-generation AAV gene therapy candidate, in ambulant boys with Duchenne.

Three participants have been dosed so far. According to Solid, SGT-003 has been well tolerated to date, and no serious adverse events have been reported. The company plans to share safety, expression and biomarker data from these first three patients, along with a trial update, in the first quarter of 2025.

Global – October 27, 2026 -- Fifty-three boys with Duchenne muscular dystrophy have now received the investigational gene therapy SGT-003, and a Phase 3 trial is already enrolling patients in Australia and Canada. Solid Biosciences shared the update in a letter to the Duchenne community as the annual Parent Project Muscular Dystrophy (PPMD) conference got under way.

The Phase 1/2 trial spans ages 0 to 10

The count comes from the Phase 1/2 INSPIRE DUCHENNE trial and reflects a June 22, 2026, enrollment cutoff. Participants range from 0 to 10 years old. One of them is a 6-month-old boy who, to the company's knowledge, is the youngest child ever dosed with a microdystrophin gene therapy.

Solid reports no cases of four serious safety conditions

The company describes SGT-003 as generally well tolerated. It reports no observed cases of drug-induced liver injury, myocarditis, thrombotic microangiopathy or atypical hemolytic uremic syndrome.

United States – October 27, 2026 -- Fifteen people with Duchenne muscular dystrophy had received the investigational gene therapy SGT-003 in the INSPIRE DUCHENNE clinical study as of August 12, 2025, according to developer Solid Biosciences.

Ten trial sites span four countries

The multi-center, open-label trial now runs 10 active clinical sites in the United States, Canada, Italy, and the United Kingdom. More sites are expected to open later this year.

Solid Biosciences expects to have treated at least 20 patients aged 0 to under 12 by the end of 2025. It anticipates widening enrollment to older patients in 2026.

NEW YORK – September 17, 2026 -- A new clinical study finds that a single application of Biodance's Real Deep Hydrogel Mask returned skin to its pre-procedure baseline within hours of fractional laser treatment, a procedure known to temporarily damage the skin's protective barrier.

Researchers tested 32 participants using a split-face design.

Each participant underwent fractional laser treatment, then had the Real Deep Mask applied to one half of the face while the other half remained untreated, allowing direct comparison under identical conditions. Board-certified dermatologists Dr. Luke Maxfield and Dr. Christopher Tomassian presented the results.

Minneapolis – September 15, 2026 -- A new study suggests one simple screen protector swap could ease digital eye strain for iPhone users, just as Apple's latest lineup hits shelves. Eyesafe, a screen-health technology company, published a white paper detailing survey results from 29 adult iPhone users conducted with Southwest Eye Care, an eye clinic.

Participants chose Eyesafe's filter nearly six times more often than a standard protector

In the two-period study, each participant used their phone at least two hours daily. They wore a standard clear screen protector for two weeks, then switched to one with Eyesafe CPF70 Technology for two weeks, completing identical surveys after each phase. Overall, 62% preferred the CPF70 protector, compared with 10% who preferred the standard one; 28% reported no preference.